For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose:
This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
Status:
Recruiting
Study Date:
Tue, 09/02/2014 to Mon, 08/01/2022
Bone Marrow Disease(s):
- paroxysmal nocturnal hemoglobinuria (PNH)
Intervention:
Experimental: Reduced Toxicity Ablative Regimen
For use in patients with a matched sibling donor or unrelated UCB donor and DBA patients who are <12 years and/or have mild/moderate iron exposure.
Drug: Reduced Toxicity Ablative Regimen
Anti-thymocyte Globulin (ATG)
Fludarabine
Busulfan
Stem Cell Infusion Day 0
Experimental: Reduced Intensity Preparative Regimen
For use in patients with unrelated donor bone marrow and for DBA patients who are >12 years and/or have significant iron exposure.
Drug: Reduced Intensity Preparative Regimen
Alemtuzumab
Cyclophosphamide
Fludarabine
Total Body Irradiation (TBI)
Stem Cell Infusion Day 0
Experimental: Myeloablative Preparative Regimen
For use in patients with a matched sibling donor, unrelated umbilical cord blood and in those with severe thalassemia.
Drug: Myeloablative Preparative Regimen
Alemtuzumab
Cyclophosphamide
Busulfan
Stem Cell Infusion Day 0